Methods of treating acute leukemias with a menin inhibitor in a combination therapy
Combining a menin inhibitor with standard-of-care therapy addresses the limitations of current treatments for acute leukemias by reducing adverse events and improving clinical responses in menin-dependent subtypes like KMT2A-r and NPM1-m AML, offering targeted therapeutic options with lower toxicity.
Patent Information
- Application Number
- AU2025216013
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-05
- Filing Date
- 2025-01-27
- Publication Date
- 2026-07-16
AI Technical Summary
Current treatments for acute leukemias, particularly for menin-dependent subtypes such as KMT2A-r and NPM1-m AML, are unsatisfactory, with high relapse rates and poor survival outcomes, and are associated with significant side effects like differentiation syndrome and tumor lysis syndrome.
Combining a menin inhibitor with standard-of-care therapy, including a lead-in period with the SOC therapy, to mitigate the risk of differentiation syndrome and tumor lysis syndrome, and provide targeted therapeutic options for these difficult-to-treat leukemias.
The combination therapy reduces the risk of adverse events and improves clinical responses in AML patients, including those with high unmet need, such as KMT2A-r and NPM1-m AML, with significant clinical responses even in heavily pre-treated patients.